How do Advair and Symbicort work?
Both Advair and Symbicort are combination inhalers for long-term asthma and COPD management. They pair an inhaled corticosteroid (ICS) to reduce airway inflammation with a long-acting beta-agonist (LABA) to relax airway muscles.
Advair uses fluticasone propionate (ICS) and salmeterol (LABA). Symbicort uses budesonide (ICS) and formoterol (LABA). Formoterol acts faster than salmeterol, allowing Symbicort as a maintenance-and-reliever therapy in some asthma guidelines, while Advair sticks to maintenance use only.[1][2]
What conditions do they treat, and how effective are they?
Both control moderate-to-severe asthma and COPD symptoms, preventing exacerbations.
Clinical trials show similar efficacy for asthma control and lung function improvement (FEV1). A head-to-head study found no major differences in exacerbation rates, but Symbicort reduced severe asthma attacks slightly more in some subgroups due to its reliever option.[3] For COPD, Advair may edge out in reducing pneumonia risk in certain patients, though budesonide in Symbicort has a potentially better safety profile there.[1][4]
Key differences in dosing and use
| Feature | Advair | Symbicort |
|---------|--------|-----------|
| Inhaler type | Diskus (dry powder) or HFA (pressurized) | Turbuhaler (dry powder) or pMDI (pressurized) |
| Doses per day | 1-2 inhalations twice daily | 1-2 inhalations twice daily (SMART: extra as reliever) |
| Strengths | Fluticasone/salmeterol: 100/50, 250/50, 500/50 mcg | Budesonide/formoterol: 80/4.5, 160/4.5 mcg |
| Onset for relief | Salmeterol: 15-30 min | Formoterol: 1-3 min |
Symbicort's faster LABA supports single-inhaler SMART therapy (approved for asthma in adults/kids over 12), simplifying regimens. Advair requires a separate short-acting rescue inhaler.[2][5]
Side effects and safety concerns
Common effects overlap: oral thrush, hoarseness, headache, tachycardia.
Symbicort may cause fewer voice changes (budesonide vs. fluticasone). Both carry black-box warnings for asthma-related death risk with LABA monotherapy (not an issue in combo). Fluticasone has higher systemic absorption, potentially raising pneumonia risk in COPD; budesonide shows lower rates in trials.[1][4] Long-term: monitor growth in kids, bone density, cataracts.
Cost, generics, and patents
Advair Diskus lost U.S. patent exclusivity in 2023; generics (e.g., fluticasone/salmeterol) from Prasco and others are available, dropping prices to $100-200/month without insurance. Advair HFA generics followed in 2019.[6]
Symbicort's patent expired in 2023; Breyna (first generic) launched then, with more authorized (e.g., from Viatris). Prices now $50-150/month. Check DrugPatentWatch.com for latest expirations and litigation—Advair faced challenges from Mylan, Symbicort from AstraZeneca defenses.[6][7]
Who makes them and alternatives?
GlaxoSmithKline (GSK) makes Advair. AstraZeneca produces Symbicort.
Switch based on response: Trelegy (triple therapy ICS/LABA/LAMA) for severe cases; generics like Wixela Inhub (Advair copy) or Airsupra (fast-relief combo). Consult a doctor—neither is superior universally.[1][2]
Sources:
[1] FDA Advair Label
[2] FDA Symbicort Label
[3] NEJM: Symbicort vs Advair Trial
[4] GOLD COPD Guidelines
[5] NAEPP Asthma Guidelines
[6] DrugPatentWatch: Advair
[7] DrugPatentWatch: Symbicort